Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced its upcoming participation in the Morgan Stanley 23rd Annual Global Health Care Conference. The presentation is scheduled for Monday, September 8, 2025, at 7:45 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha annunciato la sua partecipazione al Morgan Stanley 23rd Annual Global Health Care Conference. La presentazione è programmata per lunedì 8 settembre 2025 alle 7:45 A.M. EDT.
Gli investitori potranno seguire la webcast in diretta tramite il link fornito o dalla pagina Investor Relations > Events and Presentations di Madrigal. Una replica sarà disponibile dopo l'evento.
Madrigal Pharmaceuticals (NASDAQ:MDGL) anunció su participación en la Morgan Stanley 23rd Annual Global Health Care Conference. La presentación está programada para el lunes 8 de septiembre de 2025 a las 7:45 A.M. EDT.
Los inversionistas podrán acceder a la transmisión en vivo a través del enlace proporcionado o desde la página de Investor Relations > Events and Presentations de Madrigal. Habrá una réplica disponible después del evento.
Madrigal Pharmaceuticals (NASDAQ:MDGL)는 Morgan Stanley 23rd Annual Global Health Care Conference에 참가한다고 발표했습니다. 발표는 2025년 9월 8일 월요일 동부 표준시(EDT) 기준 오전 7:45에 예정되어 있습니다.
투자자들은 제공된 링크나 Madrigal의 Investor Relations > Events and Presentations 페이지를 통해 라이브 웹캐스트에 접속할 수 있습니다. 행사 종료 후 재방송이 제공될 예정입니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL) a annoncé sa participation à la Morgan Stanley 23rd Annual Global Health Care Conference. La présentation est prévue le lundi 8 septembre 2025 à 7h45 A.M. EDT.
Les investisseurs pourront accéder au webdiffusion en direct via le lien fourni ou depuis la page Investor Relations > Events and Presentations de Madrigal. Une rediffusion sera disponible après l'événement.
Madrigal Pharmaceuticals (NASDAQ:MDGL) hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Health Care Conference angekündigt. Die Präsentation ist an Montag, dem 8. September 2025, um 7:45 A.M. EDT geplant.
Anleger können das Live-Webcast über den bereitgestellten Link oder über Madrigals Investor Relations > Events and Presentations-Seite verfolgen. Eine Wiederholung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When is Madrigal Pharmaceuticals (MDGL) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Madrigal Pharmaceuticals' (MDGL) Morgan Stanley conference presentation?
Will there be a replay available of Madrigal Pharmaceuticals' (MDGL) Morgan Stanley conference presentation?
What is the purpose of Madrigal Pharmaceuticals' (MDGL) participation in the Morgan Stanley conference?
